Targeted Cancer Imaging

Targeted Cancer Imaging: Design and Synthesis of Nanoplatforms based on Tumour Biology reviews and categorizes imaging and targeting approaches according to cancer type, highlighting new and safe approaches that involve membrane-coated nanoparticles, tumor cell-derived extracellular vesicles, circulating tumor cells, cell-free DNAs, and cancer stem cells, all with the goal of pointing the way to developing precise targeting and multifunctional nanotechnology-based imaging probes in the future. This book is highly multidisciplinary, bridging the knowledge gap between tumor biology, nanotechnology, and diagnostic imaging, and thus making it suitable for researchers ranging from oncology to bioengineering. Although considerable efforts have been conducted to diagnose, improve and treat cancer in the past few decades, existing therapeutic options are insufficient, as mortality and morbidity rates remain high. One of the best hopes for substantial improvement lies in early detection. Recent advances in nanotechnology are expected to increase our current understanding of tumor biology, allowing nanomaterials to be used for targeting and imaging both in vitro and in vivo experimental models. Gives understanding of cancer biology that is appropriate for students and researchers in engineering and nanotechnology Demonstrates cancer targeting strategies of multifunctional nanotechnology-based imaging probes Shows how to design, synthesize and apply cancer imaging nanostructures

This book introduces molecular imaging and Target Therapy in various cancers. The first part is the subjects and primary focused on the basics of nuclear physics, radiation dosimetry, nuclear medicine equipment and small animal imaging equipment. The second part is about the radiopharmaceutical and commonly used clinical radiopharmaceuticals, including positron emission imaging agent, single photon emission imaging agent, and radionuclide therapy agents as well as their radioactive preparation, quality control, and a brief clinical application were included. Also, this part introduces a number of new imaging agents which were potential value of clinical applications. In the third part, the clinical application of the conventional imaging agent 18F-FDG in different tumors and neurodegenerative diseases and 18F-Dopa imaging in the nervous system are discussed. Besides the clinical applications of 99mTc labeled radiopharmaceuticals in parathyroid disease, coronary heart disease, myocardial infarction, sentinel lymph node, metastatic bone tumors, liver and gallbladder disease in children are introduced. Finally, the applications of radionuclide 131I on treatments of Graves' disease and differentiated thyroid cancer and metastases are investigated respectively. This book is a useful reference for professionals engaged in nuclear medicine and clinical research, including clinical nuclear medicine physicians, nuclear medicine engineers and nuclear medicine pharmacists.

This volume is unique in reporting on strategies for the application of molecular targeted imaging agents such as antibodies, peptides, receptors and contrast agents in the biologic grading of tumors, differential diagnosis of tumors, prediction of therapeutic response and monitoring tumor response to treatment. It also includes updated information on the imaging of tumor angiogenesis, hypoxia, apoptosis and gene delivery as well as expression in the understanding and utility of tumor molecular biology for better cancer management.

Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets. It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future directions. With significant advances in cell biology and molecular engineering, many targeting constructs are now available that will safely deliver these highly cytotoxic radionuclides in a targeted fashion. A companion website includes the full text and an image bank.

This book, now published in its second edition, covers a wide range of topics relating to the use of radiopharmaceuticals. The basics of nuclear chemistry, radiochemistry, and radiopharmacology are considered in detail, regulatory issues are reviewed, and potential applications in drug development, translational medicine, clinical diagnostics, and targeted therapy are discussed. Compared with the first edition, the chapters on targeted therapy with alpha- and beta-emitting radiopharmaceuticals and theranostics are completely new. Other chapters have been updated and revised as necessary. Radioisotope-based molecular imaging probes (radiopharmaceuticals) provide unprecedented insights into biochemistry and function in both normal and diseased states of living systems, with unbiased in vivo measurements of regional radiotracer activities offering very high specificity and sensitivity. No other molecular imaging technology, including functional magnetic resonance imaging, can provide such high sensitivity and specificity at a tracer level. This book, written by an experienced radiochemist and scientist, offers valuable insights into the full range of applications of this technology.

This book discusses the efficacy of nanomaterial-based X-rays enhancers against cancer therapy and imaging in both in vitro and in vivo systems. Also, synthesis, mechanism, and the related biological effects are given. Moreover, nanoparticle-based contrast agents to enhance the image quality are compiled. Finally, special nanoparticle-based contrast agents to enhance the contrast for targeted cancer therapy are covered and discussed.

Targeted Molecular Imaging covers the development of novel diagnostic approaches that use an imaging probe and agent to noninvasively visualize cellular processes in normal and disease states. It discusses the concept, development, preclinical studies, and, in many cases, translation to the clinic of targeted imaging agents. The many case studies t

Measurement of solid tumor response to treatment relies mainly on imaging. WHO tumor response criteria and, more recently, RECIST (response evaluation criteria in solid tumors) have provided means to objectively measure tumor response in clinical trials with imaging. These guidelines have been rapidly adopted in clinical practice to monitor patient treatment and for therapy planning. However, relying only on anatomical information is not always sufficient when evaluating new drugs that will reduce a tumor's functionality while preserving its size. Finding more reliable and reproducible measures of tumor response is one of the most important and difficult challenges facing modern radiology as it requires an entirely new approach to imaging. The aim of this book is to address the assessment of response to treatment by adopting a multidisciplinary perspective, just as occurs in real life in a comprehensive cancer center. Oncologists and imaging experts consider two cancer models, locally advanced disease and metastatic disease, jointly exploring both conventional and advanced means of measuring response to standard treatment protocols and new targeted therapies.